SY-1425 is a selective retinoic acid receptor alpha (RARα) agonist for genomically defined subsets of patients whose disease is characterized by the overexpression of the RARA gene. SY-1425 is in clinical trials for RARA-positive patients.
SY-1425
AAMDSIF does not recommend, endorse, or make any representation about the efficacy, appropriateness or suitability of any drug, treatment or therapy listed on this website. Some therapies listed on our site are considered experimental for the treatment of bone marrow failure diseases. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding any therapy, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.